The global acute lymphocytic leukemia therapeutics market size was valued at USD 1.5 billion in 2016 and is expected to grow at a CAGR of 10.0%. Rise in incidence of Acute Lymphoblastic Leukemia (ALL) and increase in initiatives undertaken by public and private organizations are some of the key factors expected to drive market growth.